Overview / Abstract: |
Roy M. Fleischmann, MD, discusses the latest evidence for the management of patients with moderate-to-severe rheumatoid arthritis who do not achieve treatment goals with initial disease-modifying anti-rheumatic drug therapy. A key treatment principle emphasized by Dr. Fleischmann is using a treat-to-target approach guided by validated tools for assessing disease activity and patient-reported outcomes. Among the treatment options, Dr. Fleischmann highlights the pharmacology of the latest approved treatments for rheumatoid arthritis. Using case scenarios, he illustrates how they might be integrated with other therapies. CONTENT AREAS |
Expiration |
Oct 15, 2021 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Credits / Hours |
This activity is supported by an independent educational grant from Sanofi Genzyme. |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Roy M. Fleischmann, MD |
Activity Specialities / Related Topics |
Rheumatology / Arthritis, Primary Care |
Sponsors / Supporters / Grant Providers |
This activity is supported by an independent educational grant from Sanofi Genzyme. |
Keywords / Search Terms |
Annenberg Center for Health Sciences at Eisenhower Rheumatoid Arthritis Guidelines Rheumatoid Arthritis Remission Arthritis Disease remission-arthritis Free CE CME |